About Prostate Cancer
- Prostate cancer is the second most common cancer in men
- Approximately 1 in 6 men will be diagnosed with prostate cancer during his lifetime
- An estimated 904,000 new cases of prostate cancer were diagnosed. Nearly two thirds of those diagnosed were men aged 65 or older
- An estimated 258,000 men died of prostate cancer
Initially, hormone treatment slows cancer growth by blocking testosterone production, or alternatively by blocking testosterone activity. However, hormone therapy usually becomes ineffective after a period, leaving clinicians and patients to seek other options, such as chemotherapy, which can have substantial side effects.
While new therapeutic options for prostate cancer have entered the clinical landscape, treatment of metastatic disease has not improved much in recent years and further treatment options for metastatic prostate cancer patients are still needed. The life expectancy for patients with metastatic prostate cancer reaching the stage of hormone resistance is approximately 18 to 24 months.
Source: American Cancer Society, Global Cancer Facts & Figures 2nd Edition, 2008